Congratulations to Allara Zlyberberg, postdoctoral researcher in the Little Lab at the Melbourne node of the Novo Nordisk Foundation Centre for Stem Cell Medicine, reNEW, for winning first prize in the fourth ARTxSCIENCE competition.
A new review from reNEW Melbourne PhD student Serene Yeow explores emerging research avenues to better understand and treat rheumatic heart disease, a chronic and often debilitating condition caused by inflammation and long-term damage to the heart valves.
Rheumatic heart disease (RHD) arises as a serious complication of Streptococcus pyogenes infection, beginning with acute rheumatic fever and, in some patients, progressing to rheumatic valvulitis. Over time, this immune driven cascade can permanently damage heart valve tissue, frequently resulting in heart failure. With no effective medical therapies for established disease, valve surgery remains the only treatment option.
Serene Yeow, a PhD student with reNEW Melbourne based at the Murdoch Children’s Research Institute (MCRI), has authored a comprehensive review published in Nature Cardiovascular Research. The work was completed under the supervision of reNEW Melbourne Associate Investigator Dr Holly Voges and colleagues, the review revisits long‑standing immunological principles while integrating emerging molecular insights that are reshaping the scientific understanding of RHD.
“Our aim with this review was to revisit what we know about rheumatic heart disease while bringing in new perspectives made possible by recent technological advances,” said Dr Voges.
The review outlines how high-resolution profiling of peripheral blood and patient valve tissue is beginning to unlock the complexities of long-term valve disease. These approaches now enable researchers to interrogate human specific mechanisms that drive inflammation, immune dysregulation during early valve fibrosis.
“We are entering a time where we can study RHD at a depth that simply wasn’t possible before,” said Serene Yeow. “By bringing together decades of clinical understanding with new molecular data, we hope this review helps guide future research, identifying areas where stem cell medicine could be applied to bridge existing research gaps such as the development of new therapies for diagnosed patients.”
As RHD continues to disproportionately affect lower-resourced settings globally including Australia’s First Nations People, advancing foundational understanding of disease mechanisms will be essential to developing equitable and effective treatments.
